leucovorin + fluorouracil + oxaliplatin + camrelizumab + apatinib

This is a multi-agent combination therapy consisting of five drugs with distinct mechanisms of action, primarily used or investigated for advanced solid tumors such as colorectal cancer and other gastrointestinal malignancies. - **Leucovorin** is a reduced folate that enhances the cytotoxicity of fluorouracil by stabilizing its binding to thymidylate synthase[2][3]. - **Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis[2][3]. - **Oxaliplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis[4][5]. These three agents are commonly combined as the FOLFOX regimen for colorectal cancer. Adding: - **Camrelizumab**, a monoclonal antibody targeting PD‑1 on T cells, acts as an immune checkpoint inhibitor to enhance anti-tumor immunity[6][7][10]. - **Apatinib**, a small molecule tyrosine kinase inhibitor selectively targeting VEGFR2, inhibits tumor angiogenesis and has shown synergistic effects with immunotherapy agents like camrelizumab[6][7][10]. This five-drug combination aims to maximize anti-tumor efficacy through cytotoxic chemotherapy, immune checkpoint blockade, and antiangiogenic therapy. It has been studied in various advanced cancers including esophageal squamous cell carcinoma, nasopharyngeal carcinoma, adrenocortical carcinoma, among others.

Other names

FOLFOX regimen plus camrelizumab and apatinib